As of June, 12 Analysts See $-0.39 EPS for Axovant Sciences Ltd. (AXON)

May 17, 2018 - By Irene Marshall

Axovant Sciences Ltd. (NASDAQ:AXON) Corporate Logo

Investors expect Axovant Sciences Ltd. (NASDAQ:AXON)’s quarterly earnings on June, 12., RTT reports. The earnings per share diference is $0.14 or 26.42 % up from last years number. Previous year: $-0.53; Analysts forcast: $-0.39. The stock increased 5.98% or $0.07 during the last trading session, reaching $1.24.Currently Axovant Sciences Ltd. is downtrending after 90.77% change in last May 17, 2017. AXON has 448,778 shares volume. AXON underperformed the S&P 500 by 102.32%.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe.The firm is valued at $133.66 million. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer??s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.Currently it has negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Axovant Sciences Ltd. (NASDAQ:AXON) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.